288 related articles for article (PubMed ID: 15228760)
1. Impact of disease-modifying therapies on brain and spinal cord atrophy in multiple sclerosis.
Rudick RA
J Neuroimaging; 2004 Jul; 14(3 Suppl):54S-64S. PubMed ID: 15228760
[TBL] [Abstract][Full Text] [Related]
2. What is new in the treatment of multiple sclerosis?
Weinstock-Guttman B; Jacobs LD
Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
[TBL] [Abstract][Full Text] [Related]
3. Impact of neutralizing antibodies on the clinical efficacy of interferon beta in multiple sclerosis.
Vartanian T; Sölberg Sørensen P; Rice G
J Neurol; 2004 Jun; 251 Suppl 2():II25-30. PubMed ID: 15264109
[TBL] [Abstract][Full Text] [Related]
4. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.
Havrdova E; Zivadinov R; Krasensky J; Dwyer MG; Novakova I; Dolezal O; Ticha V; Dusek L; Houzvickova E; Cox JL; Bergsland N; Hussein S; Svobodnik A; Seidl Z; Vaneckova M; Horakova D
Mult Scler; 2009 Aug; 15(8):965-76. PubMed ID: 19465443
[TBL] [Abstract][Full Text] [Related]
5. Measurement of brain and spinal cord atrophy by magnetic resonance imaging as a tool to monitor multiple sclerosis.
Bakshi R; Dandamudi VS; Neema M; De C; Bermel RA
J Neuroimaging; 2005; 15(4 Suppl):30S-45S. PubMed ID: 16385017
[TBL] [Abstract][Full Text] [Related]
6. Persistence and adherence to disease modifying drugs among patients with multiple sclerosis.
Reynolds MW; Stephen R; Seaman C; Rajagopalan K
Curr Med Res Opin; 2010 Mar; 26(3):663-74. PubMed ID: 20070144
[TBL] [Abstract][Full Text] [Related]
7. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D
Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy for the treatment of multiple sclerosis: challenges and opportunities.
Stuart WH
Curr Med Res Opin; 2007 Jun; 23(6):1199-208. PubMed ID: 17559719
[TBL] [Abstract][Full Text] [Related]
9. Pathogenesis of brain and spinal cord atrophy in multiple sclerosis.
Minagar A; Toledo EG; Alexander JS; Kelley RE
J Neuroimaging; 2004 Jul; 14(3 Suppl):5S-10S. PubMed ID: 15228754
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.
Cadavid D; Wolansky LJ; Skurnick J; Lincoln J; Cheriyan J; Szczepanowski K; Kamin SS; Pachner AR; Halper J; Cook SD
Neurology; 2009 Jun; 72(23):1976-83. PubMed ID: 19279320
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of interferon beta: differences among products.
Bertolotto A; Deisenhammer F; Gallo P; Sölberg Sørensen P
J Neurol; 2004 Jun; 251 Suppl 2():II15-II24. PubMed ID: 15264108
[TBL] [Abstract][Full Text] [Related]
12. [Interferon beta-1a (Avonex TM): clinical and MRI impacts].
Vermersch P
Rev Neurol (Paris); 1999; 155 Suppl 2():S13-9. PubMed ID: 10367320
[TBL] [Abstract][Full Text] [Related]
13. Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a.
Hardmeier M; Wagenpfeil S; Freitag P; Fisher E; Rudick RA; Kooijmans M; Clanet M; Radue EW; Kappos L;
Neurology; 2005 Jan; 64(2):236-40. PubMed ID: 15668419
[TBL] [Abstract][Full Text] [Related]
14. Measurement of spinal cord atrophy in multiple sclerosis.
Lin X; Tench CR; Evangelou N; Jaspan T; Constantinescu CS
J Neuroimaging; 2004 Jul; 14(3 Suppl):20S-26S. PubMed ID: 15228756
[TBL] [Abstract][Full Text] [Related]
15. Early treatment.
Comi G
Neurol Sci; 2006 Mar; 27 Suppl 1():S8-12. PubMed ID: 16708191
[TBL] [Abstract][Full Text] [Related]
16. [Immunomodulatory therapy in multiple sclerosis].
Csépány T; Bereczki D
Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
[TBL] [Abstract][Full Text] [Related]
17. Can glatiramer acetate reduce brain atrophy development in multiple sclerosis?
Rovaris M; Comi G; Filippi M
J Neurol Sci; 2005 Jun; 233(1-2):139-43. PubMed ID: 15949501
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of intramuscular interferon beta-1a in patients with clinically isolated syndrome: analysis of subgroups based on new risk criteria.
O'Connor P; Kinkel RP; Kremenchutzky M
Mult Scler; 2009 Jun; 15(6):728-34. PubMed ID: 19482863
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis.
Zivadinov R; Reder AT; Filippi M; Minagar A; Stüve O; Lassmann H; Racke MK; Dwyer MG; Frohman EM; Khan O
Neurology; 2008 Jul; 71(2):136-44. PubMed ID: 18606968
[TBL] [Abstract][Full Text] [Related]
20. Brain and spinal cord atrophy in multiple sclerosis.
Simon JH
Neuroimaging Clin N Am; 2000 Nov; 10(4):753-70 ,ix. PubMed ID: 11359723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
